1-2 of 2
John Gutheil, MD
Close
Sort by
Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Pierluigi Porcu, MD, Brad M. Haverkos, MDMPH,MS, Onder Alpdogan, MD, Marcelo Capra, MD PhD, Tatyana A. Feldman, MD, Elizabeth Brem, MD, Anusha Vallurupalli, MD, Jonathan E. Brammer, MD, Ana Schriefer, Juliana Pereira, MD PhD, Anil Tulpule, MD, Stefan K. Barta, MD MRCP, MS, Locke J. Bryan, MD, Richard Trauger, Sebastian Obrzut, John Gutheil, MD, Afton Katkov, MSc, Robert McRae, Ivor Royston, MD, Douglas V. Faller, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 465.
https://doi.org/10.1182/blood-2019-132004
Published: 2019
Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD
Journal: Blood
Blood (2005) 106 (11): 772.
https://doi.org/10.1182/blood.V106.11.772.772
Published: 2005